The Johnson & Johnson pause, which regulators say they hope to resolve within days, comes on the heels of production issues at the Baltimore plant that produces the J& J vaccine.
Following today's positive advisory committee meeting outcome regarding the Janssen Biotech Inc. Covid-19 Vaccine, the US Food and Drug Administration has informed the sponsor that it will rapidly work toward finalisation
